194 related articles for article (PubMed ID: 28505194)
41. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
42. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
44. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.
Chien SC; Ou SM; Shih CJ; Chao PW; Li SY; Lee YJ; Kuo SC; Wang SJ; Chen TJ; Tarng DC; Chu H; Chen YT
Medicine (Baltimore); 2015 Oct; 94(43):e1751. PubMed ID: 26512568
[TBL] [Abstract][Full Text] [Related]
45. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
46. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
47. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
48. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
Chen PM; Lai TS; Chen PY; Lai CF; Wu V; Chiang WC; Chen YM; Wu KD; Tsai TJ
J Formos Med Assoc; 2014 Apr; 113(4):219-26. PubMed ID: 24512756
[TBL] [Abstract][Full Text] [Related]
49. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide.
Mamdani M; Gomes T; Greaves S; Manji S; Juurlink DN; Tadrous M; Kennedy SH; Antoniou T
JAMA Netw Open; 2019 Oct; 2(10):e1913304. PubMed ID: 31617924
[TBL] [Abstract][Full Text] [Related]
50. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
[TBL] [Abstract][Full Text] [Related]
51. New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT.
King JB; Berchie RO; Derington CG; Marcum ZA; Scharfstein DO; Greene TH; Herrick JS; Jacobs JA; Zheutlin AR; Bress AP; Cohen JB
J Am Heart Assoc; 2023 Sep; 12(17):e030311. PubMed ID: 37646208
[TBL] [Abstract][Full Text] [Related]
52. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
[TBL] [Abstract][Full Text] [Related]
53. End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
Shani M; Vinker S; Feldman L
J Clin Hypertens (Greenwich); 2017 Jun; 19(6):627-631. PubMed ID: 28177196
[TBL] [Abstract][Full Text] [Related]
54. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.
Shen J; Huang YM; Song XN; Hong XZ; Wang M; Ling W; Zhang XX; Zhao HL
J Renin Angiotensin Aldosterone Syst; 2016 Jul; 17(3):. PubMed ID: 27377659
[TBL] [Abstract][Full Text] [Related]
55. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
56. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
[TBL] [Abstract][Full Text] [Related]
57. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
[TBL] [Abstract][Full Text] [Related]
58. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
Jiang S; Fang J; Yu T; Li W
Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
